UNSPSC 51373414: Brompheniramine/codeine/guaifenesin/menthol/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373414 Brompheniramine/codeine/guaifenesin/menthol/phenylephrine/phenylpropanolamine is a Commodity code that in practice covers a broader range of pharmaceutical products and parenteral solutions rather than the specific combination drug named in the code. Recent state and local solicitations under this code reflect procurement of injectable solutions, controlled substances for healthcare delivery, and emergency medical supplies for correctional facilities and public health agencies. The Washington State Department of Corrections and Seminole County, Florida both issued competitive solicitations in 2026, signaling active demand from state corrections departments and county public health authorities. Work includes supplying parenteral nutrition solutions, intravenous products, naloxone, and drug deactivation systems with rapid-delivery requirements—parenteral nutrition bags within 24 hours of order and standard IV solutions within 8 hours for correctional healthcare settings.

Activity under this code concentrates in Washington and Florida based on the most recent posted opportunities. The Washington State Department of Corrections issued RFQ RFQQK13020 with a response deadline of October 7, 2026, seeking parenteral products and services for eight facilities across three regions (West, Central, and East), with DOC planning to award up to three contractors per region under a four-year initial term running through June 30, 2030; the solicitation required registered Washington State business licensure, Washington State Patrol NCIC clearance, and specified insurance coverage including $1 million Commercial General Liability and $2 million Professional Liability, with set-aside aspirations for small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%). Seminole County, Florida issued IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, though the posted due date in the source (July 26, 2023) appears stale relative to the June 30, 2026 posting date.